Discovery and characterization of carbamothioylacrylamides as EP2 selective antagonists

ACS Medicinal Chemistry Letters

Volumn 4, Issue 7, 2013, Pages 616-621

  Ganesh, Thota ^a   Jiang, Jianxiong ^a   Shashidharamurthy, Rangaiah ^b   Dingledine, Ray ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

acrylamides; cytokines; EP2 antagonist; EP2 receptor; Inflammation; macrophage

Indexed keywords

BUTAPROST; CYCLOOXYGENASE 2; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; MESSENGER RNA; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; TG6 129; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD BRAIN BARRIER; BRAIN TISSUE; CONTROLLED STUDY; DRUG DEVELOPMENT; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; IC 50; MACROPHAGE; MOUSE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION;

EID: 84880142216     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400112h     Document Type: Article

References (32)

1. Baumgart, D. C.; Carding, S. R. Gastroenterology 1: Inflammatory bowel disease: cause and immunobiology Lancet 2007, 369, 1627-1640
2. Chen, Y.; Chen, P.; Hanaoka, M.; Droma, Y.; Kubo, K. Enhanced levels of prostaglandin E(2) and matrix metalloproteinase-2 correlate with the severity of airflow limitation in stable COPD Respirology 2008, 13, 1014-1021
3. Lin, C. C.; Lee, I. T.; Yang, Y. L.; Lee, C. W.; Kou, Y. R.; Yang, C. M. Induction of COX-2/PGE(2)/IL-6 is crucial for cigarette smoke extract-induced airway inflammation: Role of TLR4-dependent NADPH oxidase activation Free Radical Biol. Med. 2010, 48, 240-254
4. McInnes, I. B.; Schett, G. Mechanisms of disease: the pathogenesis of rheumatoid arthritis N. Engl. J. Med. 2011, 365, 2205-2219
5. Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21, 383-421
6. Lucas, S. M.; Rothwell, N. J.; Gibson, R. M. The role of inflammation in CNS injury and disease Br. J. Pharmacol. 2006, 147, S232-S240
7. Minghetti, L. Role of inflammation in neurodegenerative diseases Curr. Opin. Neurol. 2005, 18, 315-321
8. Al-Hourani, B. J.; Sharma, S. K.; Suresh, M.; Wuest, F. Cyclooxygenase-2 inhibitors: a literature and patent review (2009-2010) Expert Opin. Ther. Pat. 2011, 21, 1339-1432
9. DeWitt, D. L. Cox-2-selective inhibitors: the new super aspirins Mol. Pharmacol. 1999, 55, 625-31
10. Aisen, P. S.; Schafer, K. A.; Grundman, M.; Pfeiffer, E.; Sano, M.; Davis, K. L.; Farlow, M. R.; Jin, S.; Thomas, R. G.; Thal, L. J.; Study, A. s. D. C. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial J. Am. Med. Assoc. 2003, 289, 2819-2826
11. Grosser, T.; Yu, Y.; FitzGerald, G. A. Emotion recollected in tranquility: lessons learned from the COX-2 saga Annu. Rev. Med. 2010, 61, 17-33
12. Narumiya, S.; Sugimoto, Y.; Ushikubi, F. Prostanoid receptors: structures, properties, and functions Physiol. Rev. 1999, 79, 1193-1226
13. Hirata, T.; Narumiya, S. Prostanoid receptors Chem. Rev. 2011, 111, 6209-6230
14. Arehart, E.; Stitham, J.; Asselbergs, F. W.; Douville, K.; MacKenzie, T.; Fetalvero, K. M.; Gleim, S.; Kasza, Z.; Rao, Y.; Martel, L.; Segel, S.; Robb, J.; Kaplan, A.; Simons, M.; Powell, R. J.; Moore, J. H.; Rimm, E. B.; Martin, K. A.; Hwa, J. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: Potential implications for cyclooxygenase-2 inhibition Circ. Res 2008, 102, 986-993
15. Cannon, C. P.; Cannon, P. J. COX-2 inhibitors and cardiovascular risk Science 2012, 336, 1386-1387
16. Egan, K. M.; Lawson, J. A.; Fries, S.; Koller, B.; Rader, D. J.; Smyth, E. M.; FitzGerald, G. A. COX-2-derived prostacyclin confers atheroprotection on female mice Science 2004, 306, 1954-1957
17. Andreasson, K. Emerging roles of PGE(2) receptors in models of neurological disease Prostaglandins Other Lipid Mediators 2010, 91, 104-112
18. Honda, T.; Segi-Nishida, E.; Miyachi, Y.; Narumiya, S. Prostacyclin-IP signaling and prostaglandin E-2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis J. Exp. Med. 2006, 203, 325-335
19. Sheibanie, A. F.; Khayrullina, T.; Safadi, F. F.; Ganea, D. Prostaglandin E-2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis Arthritis Rheum. 2007, 56, 2608-2619
20. Sheibanie, A. F.; Yen, J. H.; Khayrullina, T.; Emig, F.; Zhang, M.; Tuma, R.; Ganea, D. The proinflammatory effect of prostaglandin E-2 in experimental inflammatory bowel disease is mediated through the IL-23 → IL-17 axis J. Immunol. 2007, 178, 8138-8147
21. Bos, J. L. Epac: a new cAMP target and new avenues in cAMP research Nat. Rev. Mol. Cell Biol. 2003, 4, 733-738
22. de Rooij, J.; Zwartkruis, F. J. T.; Verheijen, M. H. G.; Cool, R. H.; Nijman, S. M. B.; Wittinghofer, A.; Bos, J. L. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP Nature 1998, 396, 474-477
23. Jiang, J.; Ganesh, T.; Du, Y.; Thepchatri, P.; Rojas, A.; Lewis, I.; Kurtkaya, S.; Li, L.; Qui, M.; Serrano, G.; Shaw, R.; Sun, A.; Dingledine, R. Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 2307-2312
24. Jiang, J.; Ganesh, T.; Du, Y.; Quan, Y.; Serrano, G.; Qui, M.; Speigel, I.; Rojas, A.; Lelutiu, N.; Dingledine, R. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2 Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 3149-54
25. Jiang, J.; Quan, Y.; Ganesh, T.; Pouliot, W. A.; Dudek, F. E.; Dingledine, R. Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 3591-3596
26. Kalgutkar, A. S.; Gardner, I.; Obach, R. S.; Shaffer, C. L.; Callegari, E.; Henne, K. R.; Mutlib, A. E.; Dalvie, D. K.; Lee, J. S.; Nakai, Y.; O'Donnell, J. P.; Boer, J.; Harriman, S. P. A comprehensive listing of bioactivation pathways of organic functional groups Curr. Drug Metab. 2005, 6, 161-225
27. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=17503974.
28. Miyazaki, I.; Simizu, S.; Ichimiya, H.; Kawatani, M.; Osada, H. Robust and systematic drug screening method using chemical arrays and the protein library: identification of novel inhibitors of carbonic anhydrase II Biosci. Biotechnol. Biochem. 2008, 72, 2739-2749
29. Bevan, C. D.; Lloyd, R. S. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates Anal. Chem. 2000, 72, 1781-1787
30. af Forselles, K. J.; Root, J.; Clarke, T.; Davey, D.; Aughton, K.; Dack, K.; Pullen, N. In vitro and in vivo characterization of PF-044189948, a novel, potent and selective prostaglandin EP2 receptor antagonist Br. J. Pharmacol. 2011, 164, 1847-1856
31. Jiang, J.; Dingledine, R. Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation J. Pharmacol. Exp. Ther. 2013, 344, 360-7
32. Quan, Y.; Jiang, J.; Dingledine, R. EP2 receptor signaling pathways regulate classical activation of microglia J. Biol. Chem. 2013, 288, 9293-9302